Compare Charles River Laboratories Intl. Inc (CRL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Novartis AG — how do they compare? Charles River Laboratories Intl. Inc trades at $282 (market cap $13.46B), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Novartis AG is far larger — about 21.9× Charles River Laboratories Intl. Inc's market cap, and Novartis AG pays a 3.07% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | NVS | |
|---|---|---|
Market Cap | $13.46B | $295.37B |
Sector | Health | Health |
52-Week High | $282.00 | $168.62 |
52-Week Low | $145.57 | $119.31 |
Enterprise Value | $16.30B | $336.69B |
Dividend Yield | — | 3.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
